Mark Lal

1.9k total citations
27 papers, 1.2k citations indexed

About

Mark Lal is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Mark Lal has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Nephrology and 6 papers in Genetics. Recurrent topics in Mark Lal's work include Renal Diseases and Glomerulopathies (12 papers), Chronic Kidney Disease and Diabetes (10 papers) and Genetic and Kidney Cyst Diseases (6 papers). Mark Lal is often cited by papers focused on Renal Diseases and Glomerulopathies (12 papers), Chronic Kidney Disease and Diabetes (10 papers) and Genetic and Kidney Cyst Diseases (6 papers). Mark Lal collaborates with scholars based in Sweden, United States and Canada. Mark Lal's co-authors include Anita Aperia, Hjalmar Brismar, Per Uhlén, Oleg Aizman, Michael J. Caplan, Jaakko Patrakka, Ann‐Christine Eklöf, Sergey Zelenin, Katsuhiko Mikoshiba and David Merrick and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Mark Lal

25 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lal Sweden 17 754 243 218 129 110 27 1.2k
Xiaoping Huang China 22 952 1.3× 69 0.3× 119 0.5× 86 0.7× 125 1.1× 63 1.6k
Bodo Brunner Germany 10 485 0.6× 181 0.7× 234 1.1× 69 0.5× 41 0.4× 19 921
Matilde S. Ayuso Spain 23 704 0.9× 70 0.3× 118 0.5× 84 0.7× 194 1.8× 94 1.4k
Athina Tzinia Greece 21 494 0.7× 80 0.3× 171 0.8× 37 0.3× 89 0.8× 35 1.2k
Gisèle Cherqui France 21 1.2k 1.6× 69 0.3× 166 0.8× 232 1.8× 168 1.5× 66 1.8k
Hisahide Takahashi Japan 26 1.1k 1.4× 327 1.3× 1.2k 5.7× 83 0.6× 92 0.8× 82 2.0k
Sarabeth Graham United States 13 514 0.7× 108 0.4× 63 0.3× 24 0.2× 38 0.3× 14 992
Jost Seibler Germany 21 1.9k 2.5× 113 0.5× 577 2.6× 90 0.7× 79 0.7× 24 2.6k
James B. Bruns United States 15 1.6k 2.1× 85 0.3× 58 0.3× 179 1.4× 122 1.1× 17 1.8k
Federica Valsecchi Netherlands 19 1.1k 1.4× 49 0.2× 53 0.2× 38 0.3× 71 0.6× 22 1.6k

Countries citing papers authored by Mark Lal

Since Specialization
Citations

This map shows the geographic impact of Mark Lal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lal more than expected).

Fields of papers citing papers by Mark Lal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lal. The network helps show where Mark Lal may publish in the future.

Co-authorship network of co-authors of Mark Lal

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lal. A scholar is included among the top collaborators of Mark Lal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lal. Mark Lal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lal, Mark, et al.. (2025). RXFP1, the relaxin receptor: Lost and found in translation. Drug Discovery Today. 30(11). 104483–104483.
2.
Granberg, Kenneth L., Shigeki Sakamaki, Masakazu Fujio, et al.. (2024). Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists. Journal of Medicinal Chemistry. 67(6). 4442–4462. 4 indexed citations
3.
Charrin, Emmanuelle, et al.. (2024). Unraveling the role of natriuretic peptide clearance receptor (NPR3) in glomerular diseases. Scientific Reports. 14(1). 11850–11850.
4.
Carracedo, Miguel, Elke Ericson, Rasmus Ågren, et al.. (2023). APOL1 promotes endothelial cell activation beyond the glomerulus. iScience. 26(6). 106830–106830. 9 indexed citations
5.
Zambrano, Sonia, Liqun He, Toshiki Kano, et al.. (2021). Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney International. 101(4). 752–765. 44 indexed citations
6.
Möller‐Hackbarth, Katja, Lwaki Ebarasi, Sonia Zambrano, et al.. (2019). Coro2b, a podocyte protein downregulated in human diabetic nephropathy, is involved in the development of protamine sulphate-induced foot process effacement. Scientific Reports. 9(1). 8888–8888. 7 indexed citations
7.
Lal, Mark & Jaakko Patrakka. (2018). Understanding Podocyte Biology to Develop Novel Kidney Therapeutics. Frontiers in Endocrinology. 9. 409–409. 30 indexed citations
8.
Perisic, Ljubica, Patricia Q. Rodriguez, Kjell Hultenby, et al.. (2015). Schip1 Is a Novel Podocyte Foot Process Protein that Mediates Actin Cytoskeleton Rearrangements and Forms a Complex with Nherf2 and Ezrin. PLoS ONE. 10(3). e0122067–e0122067. 10 indexed citations
9.
Lal, Mark, Kenneth W. Young, & Uwe Andag. (2015). Targeting the podocyte to treat glomerular kidney disease. Drug Discovery Today. 20(10). 1228–1234. 40 indexed citations
10.
Lal, Mark, Kan Katayama, Masatoshi Nukui, et al.. (2014). Rhophilin-1 Is a Key Regulator of the Podocyte Cytoskeleton and Is Essential for Glomerular Filtration. Journal of the American Society of Nephrology. 26(3). 647–662. 27 indexed citations
12.
Merrick, David, Claudia A. Bertuccio, Hannah C. Chapin, et al.. (2013). Polycystin-1 cleavage and the regulation of transcriptional pathways. Pediatric Nephrology. 29(4). 505–511. 22 indexed citations
13.
Andræ, Johanna, Hans Ehrencrona, R Gallini, et al.. (2013). Analysis of Mice Lacking the Heparin-Binding Splice Isoform of Platelet-Derived Growth Factor A. Molecular and Cellular Biology. 33(20). 4030–4040. 8 indexed citations
14.
Perisic, Ljubica, Mark Lal, Kjell Hultenby, et al.. (2012). Plekhh2, a novel podocyte protein downregulated in human focal segmental glomerulosclerosis, is involved in matrix adhesion and actin dynamics. Kidney International. 82(10). 1071–1083. 18 indexed citations
15.
Desfrère, Luc, Marie Karlsson, Hiromi Hiyoshi, et al.. (2009). Na,K-ATPase signal transduction triggers CREB activation and dendritic growth. Proceedings of the National Academy of Sciences. 106(7). 2212–2217. 57 indexed citations
16.
Lal, Mark, Xuewen Song, Jennifer L. Pluznick, et al.. (2008). Polycystin-1 C-terminal tail associates with β-catenin and inhibits canonical Wnt signaling. Human Molecular Genetics. 17(20). 3105–3117. 142 indexed citations
17.
Uhlén, Per, Mark Lal, Oleg Aizman, et al.. (2003). Cell Signaling Microdomain with Na,K-ATPase and Inositol 1,4,5-Trisphosphate Receptor Generates Calcium Oscillations. Journal of Biological Chemistry. 278(50). 50355–50361. 147 indexed citations
18.
Lal, Mark, Hjalmar Brismar, Ann‐Christine Eklöf, & Anita Aperia. (2002). Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney International. 61(6). 2006–2014. 117 indexed citations
19.
Lal, Mark, Pierre Proulx, & Richard Hébert. (1998). A role for PKCε and MAP kinase in bradykinin-induced arachidonic acid release in rabbit CCD cells. American Journal of Physiology-Renal Physiology. 274(4). F728–F735. 27 indexed citations
20.
Lal, Mark, C. Kennedy, Pierre Proulx, & Richard Hébert. (1997). Bradykinin-stimulated cPLA2phosphorylation is protein kinase C dependent in rabbit CCD cells. American Journal of Physiology-Renal Physiology. 273(6). F907–F915. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026